Advanced BioHealing is a leader in the regenerative medicine industry, specializing in the development and commercialization of cell-based and tissue-engineered products. One of its flagship offerings is the FDA-approved Dermagraft®, designed for treating diabetic foot ulcers. The company also has a robust pipeline, including a next-generation bioengineered tissue product currently undergoing clinical trials. Founded in 2003, Advanced BioHealing is a privately held entity with R&D offices in New York, NY and manufacturing operations in La Jolla, CA.
The company recently secured a significant $25.50M Series C investment on 27 February 2007. The investors contributing to this fund infusion were Canaan Partners, Safeguard Scientifics, Red Abbey Venture Partners, Channel Medical Partners, and Wheatley Partners.
Advanced BioHealing’s emphasis on pioneering breakthroughs in regenerative medicine and its successful track record in developing and commercializing innovative products position it as a compelling investment opportunity in the biotechnology and pharmaceutical sectors. With its strong investor backing and a solid product portfolio, the company stands poised for continued growth and success in addressing critical health challenges.
